PacBio @ JPM
Total revenue grew 4% (2024 $154M). Burn appears to be at roughly 2024 Q4 levels, they’re burning ~$110M/yr1. They have $280M in cash left, so a little over 2 years.
I can’t see how they can be profitable by 2027 (as previously targeted) without further cost reduction. Discussion of 2027 profitability was notably absent from the presentation.
Revio placements are down from